All In Biotech

NDA 019617 · Pfizer

Prepidil

Dinoprostone · Endocervical · Prostaglandin Analog

Last checked: Nov 20, 2026Latest source record: Jul 5, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Dec 9, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

30 Phase 3, 9 recruiting

FAERS reports

516

499 serious, 38 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 22, 2025.

INDICATIONS AND USAGE PREPIDIL Gel is indicated for ripening an unfavorable cervix in pregnant women at or near term with a medical or obstetrical need for labor induction.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 9, 1992 Original approval · Type 3 - New Dosage Form
1 products under this application
  • PREPIDIL · DINOPROSTONE 0.5MG/3GM · GEL, ENDOCERVICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dinoprostone" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy118
  • exposure during pregnancy56
  • maternal exposure during pregnancy45
  • off label use35
  • premature baby35
  • haemoglobin decreased34
  • premature delivery32
  • white matter lesion30
  • hypospadias26
  • disseminated intravascular coagulation25
  • foetal anaemia24
  • small for dates baby24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20051
200613
20073
20082
20098
201010
20119
201210
201320
20145
20158
201616
201716
201837
201911
202016
202149
202266
202386
202447
202546
202634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 274 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.